David Geldmacher, MD Assistant Professor University Memory and Cognition Center University Hospitals School of Medicine Case Western Reserve University

Education:

• 1982 - B.A., Magna Cum Lauda, Biology, Psychology - University of Rochester, Rochester,New York
• 1986 - M.D. with Certificate in Academic Research - State University of New York, Health Science Center at Syracuse, Syracuse, New York

Post Graduate Training:

• 1986-1987 Internship in Internal Medicine, Mt. Sinai Medical Center, Cleveland, Ohio
• 1987-1990 Residency in Neurology, Case Western Reserve University, Cleveland, Ohio
• 1990-1991 Post-Doctoral Fellowship in Behavioral Neurology, Center for Neuropsychological Studies, University of Florida, Gainesvile, Florida

Licensure or Certification:

• Ohio, license 58049
• Certification in Neurology, American Board of Psychiatry and Neurology, Certification 36574
• Certified Member, American Society of Neurorehabilitation, Certicate 358
• Diplomate, National Board of Medical Examiners, Diploma #330492

Associations:

• 1992 Chairman, Patient Care Committee, Neurology Service Robert Wood Johnson University Hospital, New Brunswick, New, Jersey
• 1992 Prognosis Committee, Robert Wood Jonhson University Hospital, New Brunswick, New Jersey
• 1993 Residency Review Committee, Department of Neurology, Case Western Reserve University, Cleveland, Ohio
• 1993 ElderHealth Care Task Force, University Hospitals of Cleveland, Cleveland, Ohio
• 1993 Geriatric Psychiatry Work Group, University Hospitals of Cleveland, Cleveland, Ohio
• 1993 - Present, ElderHealth Center Medical Management Committee, University Hospitals of Cleveland, Cleveland, Ohio
• 1993 - 1995 Chairman, Stroke Extended Care Path Development Committee, University Hospitals of Cleveland, Cleveland, Ohio
• 1994 Co-Chair, Investigator Interface Task Force, Alzheimer Center, University Hospitals of Cleveland, Cleveland, Ohio
• 1994 - 1998 Chairman, Committee on Equity in Professional Affairs (CEPA), Department of Neurology, Case Western Reserve University, Cleveland, Ohio
• 1995 - 1997 Faculty, Fellowship for Journalists in Biomedical Research, Case Western Reserve University School of Medicine, Cleveland, Ohio
• 1996 Rehabilitation Unit Advisory Committee, University Hospitals of Cleveland, Cleveland, Ohio
• 1996 - 1998 Computerized Medical Record Comittee, Department of Neurology, University Hospitals of Cleveland, Cleveland, Ohio
• 1996 - Present, Professional Advisory Board, Greater Cleveland Alzheimer's Association, Cleveland, Ohio

Affiliations:

• 1993 - Present, Assistant Professor, Department of Neurology, Case Western Reserve University, Cleveland, Ohio
• 1993 - Present, Assistant Director, Division of Geriatric and Behavioral Neurology, Case Western Reserve University, Cleveland, Ohio
• 1994 - Present, Clinical Director, Alzheimer Center, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio
• 1994 - Present, Director for Clinical Trials, Alzheimer Center, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio

Research:

• 1993 Shuren J, GELDMACHER DS, Heilman KM. Nonoptic aphasia. Neurology, 1993; 43(10):1900-1907.
• 1994 GELDMACHER DS, Doty L, Heilman K. Spatial performance bias in normal elderly subjects on a letter cancellation task. Neuropsychiatry, Neuropsychology, and Behavioral Neurology, 1994;7(4):275-280.
• 1994 GELDMACHER DS, Heilman KM. Visual field influence on human attentional biases. Brain and Cognition, 1994; 26:65-72.
• 1994 GELDMACHER DS, Waldman AJ, Doty L, Heilman KM. Fluoxetine in dementia of the Alzheimer's type: Prominent adverse effects and failure to improve cognition. Journal of Clinical Psychiatry 1994; 55:161.
• 1995 GELDMACHER DS, Doty L, Heilman KM. Letter cancellation performance in Alzheimer's disease. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1995; 8:259-263.
• 1996 GELDMACHER DS. Effects of stimulus number and target to distractor ratio on the performance of random array letter cancellation tasks. Brain and Cognition 1996; 32:405-415.
• 1996 Whitehouse PJ, Patterson MB, Strauss ME, GELDMACHER DS, Mack JL, Gilmore GC, Koss E. Hallucinations. International Psychogeriatrics 1996; 8(3):387-391.
• 1997 GELDMACHER DS, Hills EC. Effect of stimulus number, target-to-distractor ratio and motor speed on visuospatial search quality following traumatic brain injury. Brain Injury 1997; 11(1):59-66.
• 1997 GELDMACHER DS, Lerner AJ, Voci JM, Noelker EA, Somple LC, Whitehouse PJ. Treatment of functional decline in adults with Down's syndrome using selective serotonin reuptake inhibitor (SSRI) drugs. Journal of Geriatric Psychiatry and Neurology 1997; 10:99-104.
• 1997 GELDMACHER DS. Clinical experience with Donepezil Hydrochloride: A case study perspective. Advances In Therapy 1997; 14:305-311.
• 1998 Hills EC, GELDMACHER DS. The effect of character and array type on visual spatial search quality following traumatic brain injury. Brain Injury 1998; 12:69-76.
• 1998 Busser JC, GELDMACHER DS, Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. Journal of Neuroscience 1998, 18:2801-2807.
• 1998 GELDMACHER DS. Stimulus characteristic determine processing approach on random array letter-cancellation tasks. Brain and Cognition 1998; 36:346-354.
• 1998 Esteban-Santillan C*, Praditsuwan R*, Ueda H*, GELDMACHER DS. Clock drawing test in very mild Alzheimer's Disease. J. American Geriatrics Society 1998; 46:1266-1269.
• 1999 GELDMACHER DS, Alhaj M*. Spatial aspects of letter cancellation performance in Arabic readers. International Journal of Neuroscience 1999; 97:29-39.
• 1999 GELDMACHER DS, Riedel T. Age effects on the spatial location of errors on Random-Array Letter Cancellation Tests. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1999;12:28-34.
• 1999 Kori A*, GELDMACHER DS. Three dimensional neglect phenomena following right anterior choroidal artery infarction. Journal of the International Neuropsychological Society 1999;5:561-565.
• *designates student or trainee

Grants:

• 1992 - 1993 Principal Investigator - Grant number 36-93, Foundation of UMDNJ, Attentional allocation following traumatic brain injury.
• 1993 - 1994 Principal Investigator - Pepper/NIA Pilot Grant Program, Case Western Reserve University. Aging and continuous vaspatial search.
• 1994 - 1995 Site Principal Investigator, Eisai America, Inc. 15 week multicenter randomized, double-blind, placebo controlled evaluation of the safety and efficacy of E2020 in patients with Alzheimer's disease.
• 1994 - 1997 Site Principal Investigator, Eisai America, Inc. An open-label, multicenter, extended evaluation of the safety and efficacy of E2020 in patients with Alzheimer's disease.
• 1994 - Present, Co-Director, Clinical Core, Alzheimer's Disease Research Center University Hospitals of Cleveland/Case Western Reserve University. National Institute on Aging, Grant AG08012.
• 1995 - Present, Site Principal Investigator, NationalInstitute on Aging/Alzheimer's Disease Cooperative Study Group.
• 1995 - 1997 Site Co-Principal Investigator, SmithKline Beecham Pharmaceutical. A randomized double-blind, placebo controlled dose-ranging study of the efficacy and tolerability of SB202026 in patients suffering from dementia of the probable Alzheimer's type.
• 1995 - 1997 Site Co-Principal Investigator, SmithKline Beecham Pharmaceutical. An open label administration of SB202026 in patients suffering from probable dementia of the Alzheimer's type.
• 1996 - 1998 Principal Investigator, Eisai America Inc. A preliminary double-blind study evaluating the effect of donepezil (E2020) on visuospatial attention in patients with Alzheimer's disease.
• 1996 - 1997 Principal Investigator, Alzheimer Center Pilot Grant, Case Western Reserve University. Visual search in aging and Alzheimer's disease.
• 1997 - 1999 Principal Investigator, Novartis Pharmaceutical, An Open Label Study to Evaluate the Safety and Efficacy of 1.5 mg bid (3 mg per day) through 6 mg bid (12 mg per day) of Exelon in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting. #ENAB356.
• 1997 - Present, Principal Investigator, Eisai, Inc. A 24-week, multi-center, randomized, double-blind, placebo-controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in patients with dementia associated with Cerebrovascular Disease.

Awards:

• 1978 - 1982 New York State Regents' Scholar
• 1978 - 1982 National Merit Scholar
• 1982 Phi Beta Kappa induction
• 1985 Merck Medical Student Achievement Award, SUNY-HSC, Syracuse
• 1995 Monitors' Choice Award, Eisai America, Inc.
• 1997 - Present, Who's Who in Science and Engineering, Listing
• 1997 Distinguished Teaching Award, Department of Family Practice, Case Western Reserve University
• 1998 The Best Doctors in America Selection, Woodward/White, Inc.
• 1998 Top Doctors Listing, Cleveland Magazine
• 1999 Who's Who in The World, Nomination